alexa Cardiovascular Disease Risk Assessment Tools in HIV-Inf
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Cardiovascular Disease Risk Assessment Tools in HIV-Infected Patients - Are They Adequate?

Andrew Hickey and Shashwatee Bagchi*

University of Maryland, School of Medicine, Baltimore, MD, USA

Corresponding Author:
Shashwatee Bagchi, MD, MS
Institute of Human Virology and Division of Infectious Diseases
University of Maryland, School of Medicine
725 West Lombard Street, N359, Baltimore, MD 21201, USA
Tel: 410-706-4606
E-mail: [email protected]

Received April 27, 2016; Accepted May 21, 2016; Published May 28, 2016

Citation: Hickey A, Bagchi S (2016) Cardiovascular Disease Risk Assessment Tools in HIV-Infected Patients - Are They Adequate? J AIDS Clin Res 7:583. doi:10.4172/2155-6113.1000583

Copyright: © 2016 Hickey A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Cardiovascular disease (CVD) has become one of the leading causes of morbidity and mortality among HIVinfected patients with seropositive patients developing CVD at higher rates than seronegative patients. Therefore, it is critical to have inexpensive, non-invasive assessment tools for CVD risk assessment in HIV-infected patients. Nearly all CVD risk assessment tools were derived from the general population, and their ability to predict CVD in the HIV population has been variable. In order to more accurately predict CVD risk in HIV-infected patients, a new CVD risk assessment tool derived from the HIV population that accounted for factors specific to HIV infection, disease course, and/or sequelae of treatment with antiretroviral therapy is needed. An improved CVD risk assessment tool for HIVinfected patients will help determine which patients would most benefit from primary prevention strategies.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version